Table 1 Patient characteristics according to dosage reduction and in total
Dosage reduction | ||||||||
|---|---|---|---|---|---|---|---|---|
Yes (<=80% dosage) | No (=100% dosage) | Total | T-test Chi2 | |||||
N | (%) | N | (%) | N | (%) | p value | ||
Age | Mean/Median | 56.5 | 59.0 | 58.4 | 58.0 | 57.6 | 59.0 | .440 |
< 65 | 32 | 69.6% | 42 | 66.7% | 74 | 67.9% | .749 | |
> = 65 | 14 | 30.4% | 21 | 33.3% | 35 | 32.1% | ||
Sex | Male | 29 | 63.0% | 46 | 73.0% | 75 | 68.8% | .267 |
Female | 17 | 37.0% | 17 | 27.0% | 34 | 31.2% | ||
T stage | T3 | 17 | 37.0% | 23 | 36.5% | 40 | 36.7% | |
T4 | 22 | 47.8% | 22 | 34.9% | 44 | 40.4% | .205 | |
Tx | 7 | 15.2% | 18 | 28.6% | 25 | 22.9% | ||
N stage | N0 | 4 | 8.7% | 5 | 7.9% | 9 | 8.3% | |
N1 | 14 | 30.4% | 16 | 25.4% | 30 | 27.5% | .796 | |
N2 | 18 | 39.1% | 23 | 36.5% | 41 | 37.6% | ||
Nx | 10 | 21.7% | 19 | 30.2% | 29 | 26.6% | ||
Grading | G2 | 27 | 58.7% | 40 | 63.5% | 67 | 61.5% | |
G3 | 18 | 39.1% | 19 | 30.2% | 37 | 33.9% | .419 | |
Gx | 1 | 2.2% | 4 | 6.3% | 5 | 4.6% | ||
L stage | L0 | 6 | 13.0% | 7 | 11.1% | 13 | 11.9% | |
L1 | 23 | 50.0% | 15 | 23.8% | 38 | 34.9% | .010 | |
Lx | 17 | 37.0% | 41 | 65.1% | 58 | 53.2% | ||
V stage | V0 | 13 | 28.3% | 11 | 17.5% | 24 | 22.0% | |
V1 | 14 | 30.4% | 10 | 15.9% | 24 | 22.0% | .030 | |
Vx | 19 | 41.3% | 42 | 66.7% | 61 | 56.0% | ||
Charlson Comorbidity Score | 6 | 32 | 69.6% | 44 | 69.8% | 76 | 69.7% | |
7 | 7 | 15.2% | 13 | 20.6% | 20 | 18.3% | ||
8 | 6 | 13.0% | 4 | 6.3% | 10 | 9.2% | .336 | |
9 | 0 | 0.0% | 2 | 3.2% | 2 | 1.8% | ||
10 | 1 | 2.2% | 0 | 0.0% | 1 | 0.9% | ||
Oncological resection/Surgery | Yes | 35 | 76.1% | 37 | 58.7% | 72 | 66.1% | .059 |
No | 11 | 23.9% | 26 | 41.3% | 37 | 33.9% | ||
No. of CTX lines | 1 | 11 | 23.9% | 17 | 27.0% | 28 | 25.7% | |
2 | 23 | 50.0% | 34 | 54.0% | 57 | 52.3% | ||
3 | 11 | 23.9% | 11 | 17.5% | 22 | 20.2% | .587 | |
4 | 0 | 0.0% | 1 | 1.6% | 1 | 0.9% | ||
5 | 1 | 2.2% | 0 | 0.0% | 1 | 0.9% | ||
Biological | Yes | 21 | 45.7% | 26 | 41.3% | 47 | 43.1% | .648 |
No | 25 | 54.3% | 37 | 58.7% | 62 | 56.9% | ||
CTX regimen sequence | FOLFOX- > FOLFIRI | 30 | 65.2% | 27 | 42.9% | 57 | 52.3% | |
FOLFIRI- > FOLFOX | 3 | 6.5% | 13 | 20.6% | 16 | 14.7% | .044 | |
FOLFOX | 10 | 21.7% | 13 | 20.6% | 23 | 21.1% | ||
FOLFIRI | 3 | 6.5% | 10 | 15.9% | 13 | 11.9% | ||
Total | 46 | 100.0% | 63 | 100.0% | 109 | 100.0% | ||